1[8]Wen M, Segerer S, Dantas M,et al. Renal injury in Apolipoprotein E-Deficient mice. Lab Invest, 2002 ,82:999
2[12]Li LS, Liu ZH, Ji DX,et al. Novel effective treatment of lipoprotein glomerulopathy-immunoadsorption onto protein A. J Am Soc Nephrol, 2001,12:A0592
3[13]Ieiri N, Hotta O, Taguma Y. Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy. Am J Kidney Dis, 2003,41:244
4[14]Arai T, Yamashita S, Yamane M,et al. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy. Atherosclerosis, 2003,169: 293
5[15]Nakaji S. Current Topics on immunoadsorption therapy. Therapeutic apheresis,2001,5:301
6[16]Andrews PA, O'Donnell PJ, Dilly SA,et al. Recurrence of lipoprotein glomerulopathy after renal transplantation. Nephrol Dial Transplant,1997,12:2442
7[4]Richard P, Thomas G, Pascual de Zulueta M, et al. Common and rare genotype of human apoprotein E determined by specific restriction profiles of polymerase chain reaction amplified DNA. Clin Chem, 1994, 40:24
8[5]Saito T,Sato H,Oikawa S. Lipoprotein glomerulopathy : A new aspect of lipid induced glomerular injury. Nephrology,1995,1:17
9[6]Gerdes LU. The common polymorphism of apolipoprotein E: geographical aspects and new pathophysiological relations. Clin Chem Lab Med, 2003, 41: 628
10[7]Saito T, Oikawa S, Sato H,et al. Lipoprotein glomerulopathy: renal lipidosis induced by novel apolipoprotein E variants. Nephron, 1999,83:193
